MyoKardia, Inc. Common Stock
MYOK
MYOK was delisted on the 16th of November, 2020.
145 hedge funds and large institutions have $1.79B invested in MyoKardia, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 49 increasing their positions, 42 reducing their positions, and 13 closing their positions.
154% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 13
69% more call options, than puts
Call options by funds: $3.42M | Put options by funds: $2.03M
17% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 42
16% more funds holding
Funds holding: 125 → 145 (+20)
23% less capital invested
Capital invested by funds: $2.34B → $1.79B (-$544M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$20.2M |
| 2 |
O
OrbiMed
New York
|
+$18.4M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.9M |
| 4 |
SC
Samlyn Capital
New York
|
+$10.1M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$6.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$56M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$22M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$18.8M |
| 4 |
Millennium Management
New York
|
-$8.17M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$4.79M |
MYOK Hedge Fund Activity: Q4 2018 in Review
145 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q4 2018, worth a combined $1.79B — down 23% from $2.34B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new MYOK positions and 13 closed out — a net gain of 20 holders — while 49 added to existing stakes and 42 trimmed.
The largest buyer was BB Biotech, adding an estimated $20.2M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $56M sold.
- 145 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q4 2018, up from 125 in Q3 2018.
- Funds reported $1.79B of MyoKardia, Inc. Common Stock stock for Q4 2018, down 23% quarter-over-quarter.
- 33 funds opened new MyoKardia, Inc. Common Stock positions in Q4 2018 and 13 closed out, a net change of +20 holders.
- The largest MyoKardia, Inc. Common Stock buyer in Q4 2018 was BB Biotech, an estimated $20.2M added.
- The largest MyoKardia, Inc. Common Stock seller in Q4 2018 was Hillhouse Investment Management, an estimated $56M sold.
Based on aggregated 13F filings for Q4 2018.